Brief: Tianjin Development Says FY Prelim Net Profit Attributable For Tianjin Lisheng Pharmaceutical RMB93.4 Mln
28/02/2023 24:50
Feb 28 (Reuters) - Tianjin Development Holdings Ltd
0882.HK :
* FY PRELIM NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG
PHARMACEUTICAL RMB93.4 MILLION VERSUS RMB122.1 MILLION
* FY PRELIM TOTAL REVENUE FROM OPERATIONS FOR TIANJIN
LISHENG
PHARMACEUTICAL RMB1.15 BILLION, UP 5.00%
Source text for Eikon: ID:nHKS11wTZN
Further company coverage: 0882.HK 002393.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tianjin Development Holdings
See all newsHong Kong's Tianjin Development HY revenue on lower pharmaceutical, utilities sales
Brief: Tianjin Development Says Teng Fei Resigns As Chairman And Executive Director
Brief: Tianjin Development Says H1 2026 Net Profit Seen At RMB 73-83 Million For Tianjin Lisheng Pharmaceutical
Brief: Tianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Million
Brief: Tianjin Development Says Tianjin Lisheng Pharmaceutical QTRLY Operating Income RMB 332.28 Mln